1 Post-Marketing Surveillance: Passive and Active Approaches and Use of Electronic Databases Karen Midthun, MD, Deputy Director Center for Biologics Evaluation.
Pharmacovigilance Audits: Is the USA behind the curve?
Regulatory submission in Japan
1 Post-marketing Safety Data Anti-Infective Drugs Advisory Committee January 8, 2003 Charles Cooper, M.D. Medical Officer Division of Anti-Infective Drug.
Pharmaceutical Development and Review Process Rev. 10/21/2014 APGO Interaction with Industry: A Medical Student Guide.
Safety of Tamiflu in Pediatric Patients – Review of Clinical Trials Data and the Scientific Literature Linda L. Lewis, M.D. Medical Officer Division of.
Acquired Resistance Patient Forum
Emerging Trends in Regulatory Biostatistics - What might be their impact ? Robert T. O’Neill Ph.D. Director, Office of Biostatistics Office of Translational.
Evaluating the Risks of Drugs and Surgery Diana Clare Spear Biochemistry Program, Beloit College, Beloit, WI ABSTRACT The pharmaceutical industry spends.
